ResMed (RMD) reported key upgrades to its Astral life support ventilators, including Optional AutoEPAP in iVAPS for U.S. patients, a high-demand therapy option. These significant upgrades make Astral one of the most advanced life support ventilators on the market. It’s already proven to stabilize ventilation in significantly fewer breaths than its leading competitor, and these innovations offer greater ease of use and even more peace of mind to patients across a wide range of respiratory diseases than ever before.
http://crweworld.com/article/news-p...ife-support-ventilator-now-has-autoepap-in-us
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$41.25 |
Change
0.120(0.29%) |
Mkt cap ! $23.89B | |||
| Open | High | Low | Value | Volume |
| $41.47 | $41.47 | $41.23 | $34.47M | 834.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 89 | $41.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $41.50 | 1500 | 2 |
View Market Depth
| Last trade - 16.10pm 12/09/2025 (20 minute delay) ? |
| RMD (ASX) Chart |